MA32554B1 - Vaccin contre hpv - Google Patents

Vaccin contre hpv

Info

Publication number
MA32554B1
MA32554B1 MA33605A MA33605A MA32554B1 MA 32554 B1 MA32554 B1 MA 32554B1 MA 33605 A MA33605 A MA 33605A MA 33605 A MA33605 A MA 33605A MA 32554 B1 MA32554 B1 MA 32554B1
Authority
MA
Morocco
Prior art keywords
dose
hpv
vaccine against
vaccine
against hpv
Prior art date
Application number
MA33605A
Other languages
Arabic (ar)
English (en)
Inventor
Dominique Descamps
Sandra Giannini
Nicolas Lecrenier
Jean Stephenne
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA32554B1 publication Critical patent/MA32554B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur l'utilisation de particules pseudo-virales (VLP) de HPV 16 et de HPV 18 associées à un excipient pharmaceutiquement acceptable, dans le cadre d'un vaccin pour la prévention des maladies ou infections liées au papillomavirus humain, ledit vaccin étant formulé pour une administration conforme à un régime posologique à deux doses constitué d'une première dose et d'une seconde dose.
MA33605A 2008-07-31 2011-02-11 Vaccin contre hpv MA32554B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8510108P 2008-07-31 2008-07-31
US17656109P 2009-05-08 2009-05-08
PCT/EP2009/059820 WO2010012780A1 (fr) 2008-07-31 2009-07-29 Vaccin contre hpv

Publications (1)

Publication Number Publication Date
MA32554B1 true MA32554B1 (fr) 2011-08-01

Family

ID=41139260

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33605A MA32554B1 (fr) 2008-07-31 2011-02-11 Vaccin contre hpv

Country Status (26)

Country Link
US (1) US20110189229A1 (fr)
EP (1) EP2318042B1 (fr)
JP (1) JP6022159B2 (fr)
KR (1) KR20110053340A (fr)
CN (1) CN102159239A (fr)
AU (1) AU2009275909A1 (fr)
BR (1) BRPI0916732B1 (fr)
CA (1) CA2732436C (fr)
CO (1) CO6341567A2 (fr)
DK (1) DK2318042T3 (fr)
DO (1) DOP2011000031A (fr)
EA (1) EA201170264A1 (fr)
ES (1) ES2519490T3 (fr)
HR (1) HRP20141063T1 (fr)
IL (1) IL210977A0 (fr)
MA (1) MA32554B1 (fr)
MX (1) MX2011001218A (fr)
NZ (1) NZ590919A (fr)
PE (1) PE20110327A1 (fr)
PL (1) PL2318042T3 (fr)
PT (1) PT2318042E (fr)
RS (1) RS53607B1 (fr)
SI (1) SI2318042T1 (fr)
SM (1) SMT201400170B (fr)
WO (1) WO2010012780A1 (fr)
ZA (1) ZA201100889B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010264695A1 (en) 2009-06-25 2012-01-19 Glaxosmithkline Biologicals S.A. Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease
CN102178944A (zh) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用
CN102229660B (zh) * 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
EP3191505A2 (fr) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
RU2628693C1 (ru) * 2016-11-10 2017-08-21 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP1732598A4 (fr) * 2003-12-31 2009-08-26 Pharmexa Inc Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques
AR049354A1 (es) * 2004-06-16 2006-07-19 Glaxosmithkline Biolog Sa VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US20090181052A1 (en) * 2005-04-26 2009-07-16 Glaxosmithkline Biologicals Sa Vaccine

Also Published As

Publication number Publication date
CO6341567A2 (es) 2011-11-21
SMT201400170B (it) 2015-01-15
PE20110327A1 (es) 2011-06-29
NZ590919A (en) 2012-10-26
JP2011529475A (ja) 2011-12-08
HRP20141063T1 (hr) 2015-01-02
DK2318042T3 (da) 2014-11-10
ZA201100889B (en) 2012-04-25
US20110189229A1 (en) 2011-08-04
BRPI0916732A2 (pt) 2017-01-31
DOP2011000031A (es) 2011-02-28
MX2011001218A (es) 2011-03-15
PT2318042E (pt) 2014-11-05
JP6022159B2 (ja) 2016-11-09
EP2318042B1 (fr) 2014-08-20
PL2318042T3 (pl) 2015-02-27
AU2009275909A1 (en) 2010-02-04
IL210977A0 (en) 2011-04-28
BRPI0916732B1 (pt) 2021-06-29
EP2318042A1 (fr) 2011-05-11
RS53607B1 (en) 2015-04-30
CN102159239A (zh) 2011-08-17
CA2732436A1 (fr) 2010-02-04
WO2010012780A1 (fr) 2010-02-04
SI2318042T1 (sl) 2014-12-31
ES2519490T3 (es) 2014-11-07
KR20110053340A (ko) 2011-05-20
EA201170264A1 (ru) 2011-08-30
CA2732436C (fr) 2018-01-16

Similar Documents

Publication Publication Date Title
MA32554B1 (fr) Vaccin contre hpv
Westrich et al. Evasion of host immune defenses by human papillomavirus
Hézode et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
WO2018005519A3 (fr) Associations médicamenteuses pour le traitement du cancer
Lee et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
WO2007016563A3 (fr) Formulations pharmaceutiques resistantes a l'alcool
JP2013505282A5 (fr)
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
JP2015533376A5 (fr)
TW200628182A (en) Injection device for administering a medication liquid
NI201300008A (es) El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isómero posicional
JP2011529475A5 (fr)
WO2005010022A3 (fr) Polypeptide agoniste de recepteur destine a la toxine zot et a la zonuline
CN103096885A (zh) 不饱和脂肪酸用于抑制病毒复制和/或感染的用途
Sattar et al. Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus
MD3121G2 (ro) Metodă de profilaxie a hepatitei virale B
SG170646A1 (en) Composition comprising vlp and amyloid-beta peptide
GB2446748A (en) Vaccine
HRP20151389T1 (hr) Antivirusni 2,5-dibenzimidazol-5-il-1-fenil-pirolidinderivat
CY1115704T1 (el) Εμβολιο κατα του hpv
Bean et al. On-treatment elevation in hepatic transaminases during HCV treatment with ombitasvir, paritaprevir, dasabuvir, ritonavir, and ribavirin: a case series
Almadiyeva et al. Comparative Effectiveness of Triple Therapy Versus Dual Therapy for Chronic Hepatitis C Virus Infection in Kazakhstan